AS­CO17: Chi-Med spot­lights pos­i­tive colon can­cer da­ta as part­ner Eli Lil­ly preps land­mark Chi­na roll­out

Hutchi­son Chi­na MediTech has tak­en an­oth­er step for­ward in a ma­jor rite of pas­sage for this ground­break­ing Chi­nese biotech. The com­pa­ny ar­rived at AS­CO with pos­i­tive da­ta on their lead drug fruquin­tinib in colon can­cer. And now it will pur­sue a speedy ap­proval in Chi­na as its part­ner Eli Lil­ly gets ready to roll out a new mar­ket­ing ef­fort.

The da­ta all lined up in the com­pa­ny’s fa­vor, with an over­all sur­vival rate of 9.3 months com­pared to 6.57 months in the place­bo arm. The me­di­an pro­gres­sion-free sur­vival rate hit 3.71 months com­pared to 1.84 months for the con­trol group. While not a rad­i­cal im­prove­ment, the da­ta line up as ap­prov­able — un­less some nasty sur­prise erupts.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER